Stocks
Repligen CorporationRGEN
NASDAQHealthcareBiotechnology$114.20+0.39%
Price as of · delayed, not real-time
Specializing in bioprocessing technologies, this company develops and supplies systems, consumables, and reagents used in biologic drug manufacturing. Its products are critical for biopharmaceutical production, making it a key player in the bioprocessing supply chain that investors monitor for growth in biologics manufacturing.
Market Cap: $6.4B52W Range: $102.97 – $175.77
Congressional Interest in Repligen Corporation (RGEN)
4 members of Congress have disclosed 9 trades in Repligen Corporation (RGEN), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 5 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
9
Unique Politicians
4
Buys
4
Sells
5
Who in Congress Is Trading RGEN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-31 | Lisa McClain | sell | $1K – $15K |
| 2025-10-30 | Lisa McClain | sell | $1K – $15K |
| 2025-10-30 | Lisa McClain | buy | $1K – $15K |
| 2025-07-22 | Lisa McClain | buy | $1K – $15K |
| 2025-06-17 | Lisa McClain | sell | $1K – $15K |
| 2025-06-11 | Lisa McClain | buy | $1K – $15K |
| 2025-04-07 | Jefferson Shreve | sell | $15K – $50K |
| 2022-05-05 | Rohit Khanna | sell | $1K – $15K |
| 2016-02-19 | MICHAEL T. MCCAUL | buy | $1K – $15K |